Bio Green Med Solution, Inc.

BGMS

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

$0.8718

+$0.0218 · +2.56%

Company profile

Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.

Bio Green Med Solution, Inc.

BGMS

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Regular session

$0.8718

+$0.0218 · +2.56%

Oct 8, 10:15 AM ET

Latest quote

$0.8718

+$0.0218 · +2.56%

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

44/ 100

GoAI Score

Hold

Valuation

Undervalued

Sentiment

Mixed

Risk

High Risk

Momentum

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Industry: Medical - Pharmaceuticals
Sector: Healthcare
Headquarters: MY
CEO: Sing Ee Wong
Listed since: Sep 12, 2025
Employees: 12

Market position

Day range

Current $0.8718

$0.78$0.8999

52-week range

Current $0.8718

$0.5664$6.70

Open: $0.8408
Previous close: $0.85
Volume: 1.6K; 0× average
Average volume: 2.32M; Average daily volume
Market cap: 4.81M USD
Beta: -0.38; Market reference 1
50-day average: $0.905; -3.67% below average
200-day average: $1.0094; -13.63% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: -269.09K USD
P/E (TTM): -0.24×
P/B (TTM): 0.68×
P/S (TTM): 2.59×
EV / EBITDA: 0.03×
Earnings yield: -92.71%
Free cash flow yield: -147.50%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 19.34%
Operating margin: -147.13%
Net margin: -118.27%
Return on equity: -43.82%
Return on assets: -36.63%
Return on invested capital: -122.97%

Financial health

Debt / equity: 0×
Current ratio: 4.7×
Altman Z-score: -77.16
Piotroski F-score: 4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

747K USD+1637.21%

Operating income

−8.43M USD+29.80%

Net income

−3M USD+73.26%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	747K USD	43K USD	420K USD	—	—
Cost of goods sold	609K USD	—	—	32K USD	43K USD
Gross profit	138K USD	43K USD	420K USD	−32K USD	−43K USD
Research and development	848K USD	6.66M USD	19.16M USD	20.27M USD	14.93M USD
Selling, general, and administrative	7.72M USD	5.39M USD	6.72M USD	7.38M USD	7.46M USD
Operating expenses	8.57M USD	12.05M USD	25.87M USD	27.66M USD	22.39M USD
Interest income	62K USD	12K USD	266K USD	210K USD	16K USD
Depreciation and amortization	5K USD	6K USD	31K USD	32K USD	43K USD
Operating income	−8.43M USD	−12M USD	−25.45M USD	−27.66M USD	−22.39M USD
Net income	−3M USD	−11.21M USD	−22.56M USD	−21.2M USD	−18.46M USD

Company facts updated Oct 8, 2026.

Earnings

EPS beat rate: 78%; 7 beats, 2 misses, 0 met estimates
Average EPS surprise: +60.31%; 9 comparable reports
Latest EPS result: -0.08

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

BGMS news

globenewswire.comSep 30, 2026

$HAREHOLDER ALERT - The M&A Class Action Firm Continues to Investigate the Merger— ATKR, BZH, BGMS and CBAN

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a…

Read source

defenseworld.netSep 28, 2026

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Up 160.2% in September

Cyclacel Pharmaceuticals, Inc. (NASDAQ: BGMS - Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 90,785 shares, a growth of 160.2%…

Read source

globenewswire.comSep 8, 2026

EQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHM

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a…

Read source

globenewswire.comAug 12, 2026

BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and…

Read source

prnewswire.comJul 27, 2026

Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Read source

defenseworld.netJul 26, 2026

Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two…

Read source

Corporate actions

Corporate action history

Action	Ex-dividend date	Details	Record date	Payment date
Dividend	Apr 29, 2025	$36.00Irregular	—	—

Dividend

Ex-dividend Apr 29, 2025

$36.00

Irregular

BGMS peers

AMGN

Amgen Inc.

$407.63

-1.32%

GILD

Gilead Sciences, Inc.

$146.32

-0.36%

ISRG

Intuitive Surgical, Inc.

$412.18

-0.56%

VRTX

Vertex Pharmaceuticals Incorporated

$501.9

-0.74%

SNY

Sanofi

$40.065

-0.34%

MRNA

Moderna, Inc.

$195.4

-0.55%

Continue in GoAI

Research BGMS

AI-generated and delayed market data for informational and educational purposes only. Not investment advice.

Regular session · ET · Market data may be delayed.

Company profile

Company website

Industry: Medical - Pharmaceuticals
Sector: Healthcare
Headquarters: MY
CEO: Sing Ee Wong
Listed since: Sep 12, 2025
Employees: 12

Market position

Day range

Current $0.8718

$0.78$0.8999

52-week range

Current $0.8718

$0.5664$6.70

Open: $0.8408
Previous close: $0.85
Volume: 1.6K; 0× average
Average volume: 2.32M; Average daily volume
Market cap: 4.81M USD
Beta: -0.38; Market reference 1
50-day average: $0.905; -3.67% below average
200-day average: $1.0094; -13.63% below average

Bio Green Med Solution, Inc.

BGMS company overview

Company profile

Bio Green Med Solution, Inc.

BGMS company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

BGMS news

$HAREHOLDER ALERT - The M&A Class Action Firm Continues to Investigate the Merger— ATKR, BZH, BGMS and CBAN

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Up 160.2% in September

EQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHM

BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Corporate actions

Corporate action history

BGMS peers

Continue in GoAI

BGMS company overview

Company profile

Market position

BGMS company overview

Company profile

BGMS company overview

Company profile

Market position

BGMS company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

BGMS news

$HAREHOLDER ALERT - The M&A Class Action Firm Continues to Investigate the Merger— ATKR, BZH, BGMS and CBAN

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Up 160.2% in September

EQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHM

BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Corporate actions

Corporate action history

BGMS peers

Continue in GoAI